A Brief Overview of Ribonucleic Acid Interference (RNAi) for Combating Immune Disorders
Author(s): Manisha Jayanand*, Sanjiv Mittal, Sushma Chaturvedi, Durgesh Wadhwa
Abstract
In almost all human cells, the RNA interference (RNAi) system controls mRNA stability as well as translation. While tiny ds RNA particles are effective in inducing RNAi silence of particular genes, their clinical application has been fraught with df?cutes about safety and ef?cc? However, in August 2018, the ?ed entered a new phase with the approval of patisiran, the very initial RNAi-based medicine, by the US Food & Drug Administration. Rapid advancements in our knowledge of RNAi-based processes have led to the use of this potent technique in gene function research as well as therapeutic applications for disease treatment. Two-dimensional pharmaceutical designs for RNAi-based treatments rely solely on the ?dg of excellent Watson-Crick base pairing between the RNAi guide strand and the target, allowing for fast construction and testing of RNAi triggers. Despite the great sec?ct of activity, siRNA may produce a series of untargeted consequences, because of the toxicity they cause, prohibit their usage at large dose. We address important breakthroughs in the development and design of RNAi medicines that led to this historic accomplishment, the present status of clinical pipeline, and possibilities for future advancements, including new RNAi pathway therapeutics that use mechanisms other than post-translational RNAi silencing